John A. Katzenellenbogen, Chairman of the SAB, received a Ph.D. in Organic Chemistry from Harvard University and holds the Swanlund Professorship of Chemistry at the University of Illinois, Urbana, where his research interests involve novel ligands and dendrimers, receptor structure and protein microarrays, combinatorial chemistry and radiopharmaceuticals. He received the Leading Edge in Basic Science Award from the Society for Toxicology in 2009 and the Gustavus John Esselen Award for Chemistry in the Public Interest in 2008, among many other awards.
Frank H. Eeckman received his M.D. cum laude from the University of Ghent Medical School in Belgium, where he completed his residency in Neurology. He later received a Ph.D. in Physiology from the University of California at Berkeley, where he was a Fulbright Scholar. He served as the Senior Director of IT and Bioinformatics at GeneTrace Systems and is currently the Director of Regulatory Policy at the NeuroTechnology Industry Organization and an Analyst at NeuroInsights in San Francisco, CA.
Robert S. Negrin received his M.D. from Harvard University and currently serves as Director, Bone Marrow Transplant Program and Professor of Medicine at Stanford University Medical School, where his research concerns the biology of cells capable of inducing or suppressing graft vs. host disease as well as cells promoting a graft vs. tumor effect. Prof. Negrin previously served as the President of the American Society for Blood and Marrow Transplantation.
Ralph W. Niven received his Ph.D. in Pharmaceutical Sciences from the University of Kentucky and M.B.A. from George Washington University. He previously served as a Research Scientist at Amgen, as VP for Development at Advanced Inhalation Research (AIR) and as Senior VP for Preclinical Development at Discovery Laboratories. He is currently the Chief Technology Officer of APT Pharmaceuticals, Inc., in Burlingame, CA, and serves on the External Advisory Board of Nanotherapeutics Corporation.
Barry M. Sherman received his M.D. from the University of Michigan and is board-certified in internal medicine and endocrinology. Prior to entering the pharmaceutical industry, he was a Professor of Medicine and Endocrinology at the University of Iowa. He was a founder of BiPar Sciences, Inc., in Brisbane, CA, where he served as the Executive VP for Development and currently serves on the Innovation Board. Earlier, he was the first Senior VP and Chief Medical Officer of Genentech and later served as the President and CEO of Anergen, Inc.Michael G. Shulman received his M.D. from Columbia University and was in private practice in internal medicine, nephrology and hypertension for 17 years before entering the pharmaceutical industry. He has held positions at or served as a consultant to Sandoz, Syntex, Genentech, Anergen, Alza Corporation, Celtic Pharma Development, Kowa Research Institute, Reuters Insight Expert Network, and Marion Weinreb & Associates, among others. His consultancy in San Francisco, CA, is called BioMedical Resources for Global Drug Development.